



November 7, 2012

## **TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2012 Financial Results**

### **Investor Conference Call to be Held Friday, November 9, 2012 at 8:30am EST**

NEW YORK, Nov. 7, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (OTCBB:TGTX), an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced that a conference call will be held on Friday, November 9, 2012 at 8:30 a.m. EST to discuss results for the third quarter ended September 30, 2012 and a business outlook for the remainder of 2012. Michael S. Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Third Quarter Earnings Call. The audio recording of the conference call will be available for replay at <http://www.tgtherapeutics.com>, for a period of 30 days after the call.

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

### **ABOUT TG THERAPEUTICS, INC.**

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. TG Therapeutics is also developing TGR-1202, a highly specific, orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B - lymphocytes. TG Therapeutics is headquartered in New York City.

The TG Therapeutics logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=11857>

TGTX - G

CONTACT: Jenna Bosco

Director - Investor Relations

TG Therapeutics, Inc.

Telephone: 212.554.4484

Email: [ir@tgtxinc.com](mailto:ir@tgtxinc.com)



Source: TG Therapeutics, Inc.

News Provided by Acquire Media